Drug Profile
EOS 100574
Alternative Names: A2A receptor antagonist - iTeos Therapeutics; EOS100574Latest Information Update: 10 Jun 2022
Price :
$50
*
At a glance
- Originator iTeos Therapeutics
- Class Antineoplastics
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 31 Dec 2021 iTeos Therapeutics has patents pending for A2AR program portfolio in USA and Worldwide
- 30 Dec 2021 iTeos Therapeutics has patent protection for A2AR program portfolio in USA and Australia
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in Belgium